Artios Pharma, a UK-based DNA Damage Response (DDR) company, has appointed Ian Smith as its Chief Medical Officer.
Mr Smith joins from Eli Lilly where, as a Senior Medical Director, he was responsible for the successful clinical development and worldwide regulatory approval of key breakthrough oncology medicines in multiple indications.
Previously, he spent eight years at AstraZeneca where he was involved in the early clinical development of several oncology compounds.
In his new role he will assume responsibility for leading Artios’s overall preclinical and clinical development strategy, regulatory and medical activities.
He will work in tandem with and report directly to CEO Niall Martin and join the company’s executive leadership team.
“Ian brings a wealth of experience in advancing oncology compounds from early to late stage clinical development and through to market,” said Mr Martin.
“With his expertise, and the guidance we will receive from our newly formed Clinical Advisory Board, Artios is in a strong position to accelerate the development of its pipeline of highly promising first-in-class DDR therapies.”
Mr Smith added: “I look forward to working with the rest of the management team and world-leading Clinical Advisory Board, to progress our pipeline of DDR therapies, particularly Polθ which has multiple opportunities to treat some difficult cancers, providing new treatment options for patients.”